Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it ...
In a report released today, Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report), with a ...
Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its ...
Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...
Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting ...
Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...
A study identifies promising compounds targeting PI3Kα for the treatment of triple-negative breast cancer, offering new ...
ETX-636 has a differentiated preclinical profile and the potential to deliver clinical benefit to patients with tumors harboring all forms of mutant PI3Kα. The ETX-636 preclinical data is being ...
Indianapolis: Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small ...
Report top-line results during the second half of 2025 from the APEX trial. APEX is a registration-directed, global, open-label trial of bezuclastinib in patients with Advanced Systemic Mastocytosis ...
H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on RLAY stock, giving a Buy rating yesterday.Stay Ahead of the ...
Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance ...